Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,752 result(s) found for: Respect. Displaying page 1 of 88.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001761-42 Sponsor Protocol Number: 0869-131 Start Date*: 2006-06-12
    Sponsor Name:Merck & Co., Inc
    Full Title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the ...
    Medical condition: Postoperative Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036238 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005860-69 Sponsor Protocol Number: ODEN Start Date*: 2021-05-10
    Sponsor Name:University of Gothenburg
    Full Title: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006921-14 Sponsor Protocol Number: AF-H-01 Start Date*: 2009-02-09
    Sponsor Name:ALK-Abelló Arzneimittel GmbH
    Full Title: A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQ
    Medical condition: Grass pollen induced allergic rhinoconjunctivitis requiring treatment during the grass pollen season
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000993-31 Sponsor Protocol Number: CLOU064A2201 Start Date*: 2019-04-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patien...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) HU (Completed) BE (Completed) ES (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005358-36 Sponsor Protocol Number: I8B-MC-ITRO Start Date*: 2019-03-18
    Sponsor Name:Eli Lilly and Company
    Full Title: I8B MC ITRO A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004169-41 Sponsor Protocol Number: CQAB149B2329 Start Date*: 2006-01-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients wi...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003210-27 Sponsor Protocol Number: 201663 Start Date*: 2017-07-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix, Hiberix and Prevenar 13 when co-administered with t...
    Medical condition: PCV-free HRV vaccine is indicated to prevent gastroenteritis (GE) caused by rotavirus (RV)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006088-23 Sponsor Protocol Number: MEK116513 Start Date*: 2012-06-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectab...
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) AT (Completed) NO (Completed) IE (Completed) CZ (Completed) ES (Completed) NL (Completed) HU (Completed) FI (Completed) IT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005114-18 Sponsor Protocol Number: MK-1308A-008 Start Date*: 2021-07-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-...
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079619 MSI-high LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003168-29 Sponsor Protocol Number: AGO/2018/003 Start Date*: 2019-03-15
    Sponsor Name:Ghent University Hospital
    Full Title: [18F]PSMA-11 PET/CT for prostate cancer – phase 3 clinical trial
    Medical condition: prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007876-41 Sponsor Protocol Number: 111567 Start Date*: 2008-03-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals...
    Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002143-15 Sponsor Protocol Number: RLM-MD-03 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) DK (Prematurely Ended) BG (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003231-19 Sponsor Protocol Number: GO29294 Start Date*: 2015-01-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR M...
    Medical condition: Advanced tumor and metastastic disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) PL (Completed) SI (Completed) SE (Completed) DE (Completed) GB (Completed) HU (Completed) PT (Completed) NL (Completed) FI (Completed) NO (Completed) DK (Completed) BE (Completed) AT (Completed) ES (Completed) FR (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-000758-28 Sponsor Protocol Number: 19767 Start Date*: 2022-11-23
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibito...
    Medical condition: Prevention of stroke or systemic embolism in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    21.1 10042613 - Surgical and medical procedures 10049910 Thromboembolism prophylaxis LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) SE (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) LT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001783-34 Sponsor Protocol Number: MK-0517-044 Start Date*: 2015-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015018-23 Sponsor Protocol Number: CACZ885H2356 Start Date*: 2009-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tol...
    Medical condition: Treatment and prevention of gout flares in patients with frequent flares and for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) LT (Completed) SE (Completed) EE (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003607-22 Sponsor Protocol Number: CCFZ533A2201 Start Date*: 2018-07-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody...
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) NO (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002510-36 Sponsor Protocol Number: CAIN457A2307 Start Date*: 2011-12-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in subjects wit...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) GB (Completed) DE (Completed) AT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001267-36 Sponsor Protocol Number: CO-160310091324-SCCT Start Date*: 2016-06-08
    Sponsor Name:McNeil AB
    Full Title: PHARMACODYNAMIC EFFECTS OF NICOTINE MOUTH SPRAY AND CYTISINE TABLET. A STUDY IN HEALTHY SMOKERS.
    Medical condition: Tobacco Dependence
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:55:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA